Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9

UK Ballehaninna, RS Chamberlain - Tumor Biology, 2013 - Springer
Pancreatic adenocarcinoma accounts for nearly 90–95% of exocrine malignant tumors of
the pancreas. Traditionally, overexpressed proteins/epitopes such as CA 19-9, CA-50, CEA …
被引用次数：140 相关文章

Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9

UK Ballehaninna, RS Chamberlain - Tumor Biology, 2013 - search.proquest.com
Pancreatic adenocarcinoma accounts for nearly 90-95% of exocrine malignant tumors of the
pancreas. Traditionally, overexpressed proteins/epitopes such as CA 19-9, CA-50, CEA, and …

Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9.

UK Ballehaninna, RS Chamberlain - Tumour Biology: the Journal of …, 2013 - europepmc.org
Pancreatic adenocarcinoma accounts for nearly 90-95% of exocrine malignant tumors of the
pancreas. Traditionally, overexpressed proteins/epitopes such as CA 19-9, CA-50, CEA, and …

Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9

UK Ballehaninna… - Tumour biology: the …, 2013 - pubmed.ncbi.nlm.nih.gov
Pancreatic adenocarcinoma accounts for nearly 90-95% of exocrine malignant tumors of the
pancreas. Traditionally, overexpressed proteins/epitopes such as CA 19-9, CA-50, CEA, and …

Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9

UK Ballehaninna, RS Chamberlain - Tumor Biology, 2013 - infona.pl
Pancreatic adenocarcinoma accounts for nearly 90–95% of exocrine malignant tumors of
the pancreas. Traditionally, overexpressed proteins/epitopes such as CA 19-9, CA-50, CEA …

[引用][C] Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9

UK Ballehaninna, RS Chamberlain - Tumor biology, 2013 - Springer